NITI Aayog CEO Amitabh Kant 
Business

India scaling up production of APIs: NITI Aayog CEO Amitabh Kant

India, a global hub for generic drugs, has launched a new scheme to boost production of active pharmaceutical ingredients (APIs) that are greatly dependent on the Chinese supply chain, according to NITI Aayog CEO Amitabh Kant.

migrator

New Delhi

Speaking at the 14th Annual BioPharma and Healthcare Summit, he said India is now gearing up for innovation in its pharmaceutical ecosystem focusing on speedy and scaled up delivery of new vaccines and personalised medicines.

He said India has launched a new scheme to boost production of active pharmaceutical ingredients that are greatly dependent on the Chinese supply chain. “We are planning to do complete manufacturing in India,” he said at the recently-held virtual summit organised by the USA-India Chamber of Commerce.

The summit was attended by major players from the US pharma sector, whose combined annual R&D budget is over $45 billion.

Visit news.dtnext.in to explore our interactive epaper!

Download the DT Next app for more exciting features!

Click here for iOS

Click here for Android

Did reversing police vehicle cause accident of two-wheeler chasing Vijay convoy in Thanjavur?

Second bomb threat at Chennai bank in 24 hours; Rajaji Salai building evacuated

Is documentary on Ajith's racing career hitting the big screen?

Nepal records 6% turnout till 9.30 am in first election since govt-toppling Gen Z protests last year

Rs 100 crore Pollachi coir exports hit in a week due to West Asia war